Clin2Atlas
AtlasCancersNeoplasms

Prostate cancer

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Flutamide approved (FDA)1991 — Histrelin approved (FDA)1992 — Finasteride approved (FDA)1995 — Docetaxel anhydrous approved (FDA)1996 — Nilutamide approved (FDA)1997 — Tamsulosin approved (FDA)2000 — Triptorelin approved (FDA)2000 — Isopropyl alcohol approved (FDA)2001 — Zoledronic acid anhydrous approved (FDA)2001 — Dutasteride approved (FDA)2008 — Degarelix approved (FDA)2010 — Cabazitaxel approved (FDA)2011 — Abiraterone acetate approved (FDA)2012 — Choline approved (FDA)2012 — Enzalutamide approved (FDA)2013 — Autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous cd54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor approved (FDA)2013 — Radium dichloride approved (FDA)2014 — Olaparib approved (FDA)2016 — Fluciclovine approved (FDA)2018 — Apalutamide approved (FDA)2019 — Darolutamide approved (FDA)2021 — Piflufolastat approved (FDA)2022 — Vipivotide tetraxetan lutetium approved (FDA)
1989: Drug approval — Flutamide approved (FDA). 1991: Drug approval — Histrelin approved (FDA). 1992: Drug approval — Finasteride approved (FDA). 1995: Drug approval — Docetaxel anhydrous approved (FDA). 1996: Drug approval — Nilutamide approved (FDA). 1997: Drug approval — Tamsulosin approved (FDA). 2000: Drug approval — Triptorelin approved (FDA). 2000: Drug approval — Isopropyl alcohol approved (FDA). 2001: Drug approval — Zoledronic acid anhydrous approved (FDA). 2001: Drug approval — Dutasteride approved (FDA). 2008: Drug approval — Degarelix approved (FDA). 2010: Drug approval — Cabazitaxel approved (FDA). 2011: Drug approval — Abiraterone acetate approved (FDA). 2012: Drug approval — Choline approved (FDA). 2012: Drug approval — Enzalutamide approved (FDA). 2013: Drug approval — Autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous cd54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor approved (FDA). 2013: Drug approval — Radium dichloride approved (FDA). 2014: Drug approval — Olaparib approved (FDA). 2016: Drug approval — Fluciclovine approved (FDA). 2018: Drug approval — Apalutamide approved (FDA). 2019: Drug approval — Darolutamide approved (FDA). 2021: Drug approval — Piflufolastat approved (FDA). 2022: Drug approval — Vipivotide tetraxetan lutetium approved (FDA)

What's being tested now

2002: 1 trials started2003: 2 trials started2004: 3 trials started2005: 1 trials started2007: 4 trials started2008: 3 trials started2009: 4 trials started2010: 3 trials started2011: 5 trials started2012: 6 trials started2013: 10 trials started2014: 13 trials started2015: 17 trials started2016: 17 trials started2017: 22 trials started2018: 33 trials started2019: 59 trials started2020: 60 trials started2021: 91 trials started2022: 90 trials started2023: 168 trials started2024: 267 trials started2025: 300 trials started2026: 335 trials started201020202026335

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 1432 active Castration Resistant Prostatic Cancer trials on Clin2 →

Related

Lip and oral cavity cancerNasopharynx cancerOther pharynx cancerEsophageal cancerStomach cancerColon and rectum cancerGallbladder and biliary tract cancerPancreatic cancerLarynx cancerTracheal, bronchus, and lung cancerMalignant skin melanomaSoft tissue and other extraosseous sarcomas

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.